DIA 3rd Cardiac Safety Workshop Explores the Future of the TQT Study And Issues Surrounding the Conduct and Analysis of TQT Studies in Japan

Posted:
9
May 2012

Dr J�rg T�ubel, will be presenting again at the DIA 3rd Cardiac Safety Workshop in Japan, taking place in Tokyo from 28-29 May 2012.The 3rd Cardiac Safety Workshop in Japan will explore topics surrounding the future of the TQT study, including the emerging intensive QT studies, the use of positive controls for assay sensitivity, the risks involved in TQT studies, as well as other issues specific to Japan. The meeting will bring together experts and members of academia, regulatory and drug development organisations for 2 days of intensive discussion, debates and updates.Dr Taubel's extensive experience in investigating ethnic differences and bridging ECG studies exploring physiological and drug induced effects makes him a world leading expert in the evaluation of effects of ethnicity on the ECG. His recent work includes studies in both Caucasian and Japanese participants using techniques such as an euglycaemic insulin clamp investigating the effects of food on the QT interval in a proper ICH E14 setting. He will present some of his latest data.Click here to view the full programWe invite you to be a part of this hugely informative event on current issues facing the industry and network with like-minded scientific professionals. A Business Development representative from Richmond Pharmacology will also be standing by for the duration of the workshop to discuss your prospective TQT study requirements and how we can benefit towards its total success.To arrange a face to face meeting or request a copy of our latest TQT publication,contact a member of our BD Team today.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more